Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors
Journal
Journal of Thoracic Oncology
Journal Volume
12
Journal Issue
5
Pages
e49-e51
Date Issued
2017
Author(s)
SDGs
Other Subjects
anaplastic lymphoma kinase; anaplastic lymphoma kinase inhibitor; belizatinib; ceritinib; crizotinib; thyroid transcription factor 1; anaplastic lymphoma kinase; protein kinase inhibitor; protein tyrosine kinase; adrenal metastasis; adult; ALK gene; brain metastasis; bronchus biopsy; cancer resistance; cancer staging; case report; controlled study; drug dose sequence; drug response; EML4 gene; gene; gene rearrangement; genetic analysis; genotype; human; human cell; human tissue; immunohistochemistry; Letter; male; middle aged; non small cell lung cancer; pleura effusion; point mutation; reverse transcription polymerase chain reaction; RNA extraction; spinal cord metastasis; spleen metastasis; tumor growth; antagonists and inhibitors; drug resistance; enzymology; genetics; lung tumor; mutation; non small cell lung cancer; pathology; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases
Publisher
Elsevier Inc
Type
letter